SG10201811586YA - Composite formulation for oral administration comprising ezetimibe and rosuvastatin and a process for the preparation thereof - Google Patents

Composite formulation for oral administration comprising ezetimibe and rosuvastatin and a process for the preparation thereof

Info

Publication number
SG10201811586YA
SG10201811586YA SG10201811586YA SG10201811586YA SG10201811586YA SG 10201811586Y A SG10201811586Y A SG 10201811586YA SG 10201811586Y A SG10201811586Y A SG 10201811586YA SG 10201811586Y A SG10201811586Y A SG 10201811586YA SG 10201811586Y A SG10201811586Y A SG 10201811586YA
Authority
SG
Singapore
Prior art keywords
ezetimibe
rosuvastatin
oral administration
preparation
composite formulation
Prior art date
Application number
SG10201811586YA
Inventor
Yong Il Kim
Ha Young Jeong
Kyeong Soo Kim
Seung Jun Lee
Jae Hyun Park
Jong Soo Woo
Original Assignee
Hanmi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54938391&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201811586Y(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hanmi Pharmaceutical Co Ltd filed Critical Hanmi Pharmaceutical Co Ltd
Publication of SG10201811586YA publication Critical patent/SG10201811586YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMPOSITE FORMULATION FOR ORAL ADMINISTRATION COMPRISING EZETIMIBE AND ROSUVASTATIN AND A PROCESS FOR THE PREPARATION THEREOF Provided is a solid composite formulation for oral administration that includes: an ezetimibe-wet granule portion including ezetimibe that is wet-granulated using a fluid-bed granulator; and a rosuvastatin mixture portion including rosuvastatin or a pharmaceutically acceptable salt thereof. [No suitable figure]
SG10201811586YA 2014-06-25 2015-06-09 Composite formulation for oral administration comprising ezetimibe and rosuvastatin and a process for the preparation thereof SG10201811586YA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020140078388A KR101977785B1 (en) 2014-06-25 2014-06-25 Composite formulation for oral administration comprising ezetimibe and rosuvastatin and a process for the preparation thereof

Publications (1)

Publication Number Publication Date
SG10201811586YA true SG10201811586YA (en) 2019-02-27

Family

ID=54938391

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201610748RA SG11201610748RA (en) 2014-06-25 2015-06-09 Composite formulation for oral administration comprising ezetimibe and rosuvastatin and a process for the preparation thereof
SG10201811586YA SG10201811586YA (en) 2014-06-25 2015-06-09 Composite formulation for oral administration comprising ezetimibe and rosuvastatin and a process for the preparation thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201610748RA SG11201610748RA (en) 2014-06-25 2015-06-09 Composite formulation for oral administration comprising ezetimibe and rosuvastatin and a process for the preparation thereof

Country Status (10)

Country Link
KR (1) KR101977785B1 (en)
AR (1) AR100977A1 (en)
BR (1) BR112016030111A2 (en)
CL (1) CL2016003283A1 (en)
EC (1) ECSP16096477A (en)
JO (1) JOP20150154B1 (en)
SG (2) SG11201610748RA (en)
TW (1) TWI700100B (en)
UY (1) UY36190A (en)
WO (1) WO2015199356A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ2016538A3 (en) 2016-09-05 2018-03-14 Zentiva, K.S. A pharmaceutical composition comprising two different active ingredients
CZ2016539A3 (en) * 2016-09-05 2018-03-14 Zentiva, K.S. A pharmaceutical composition comprising two different active substances and a method of its preparation
KR102206535B1 (en) * 2016-11-29 2021-01-22 한미약품 주식회사 Oral composite tablet comprising ezetimibe and rosuvastatin
EP3437636A1 (en) * 2017-08-02 2019-02-06 Adamed sp. z o.o. Pharmaceutical composition comprising ezetimibe
KR102500643B1 (en) * 2019-04-18 2023-02-16 한미약품 주식회사 Pharmaceutical combination preparation comprising ezetimibe and losartan
KR20200137243A (en) 2019-05-29 2020-12-09 콜마파마(주) Process for preparation of pharmaceutical combination containing ezetimibe and rosuvastatin
BR112022001783A2 (en) 2019-07-31 2022-03-22 Tecnimede Soc Tecnico Medicinal Sa Immediate release multi-unit solid oral compositions, their methods and uses.
BR112023003323A2 (en) * 2020-08-25 2023-03-21 Daewoong Pharmaceutical Co Ltd PHARMACEUTICAL COMPOSITION IN SINGLE DOSAGE FORM

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100907144B1 (en) * 2007-09-05 2009-07-09 박재섭 The golf club using moving ball
WO2009024889A2 (en) * 2007-08-21 2009-02-26 Ranbaxy Laboratories Limited Pharmaceutical composition comprising a hmg-coa reductase inhibitor and ezetimibe
WO2011019326A2 (en) * 2009-07-02 2011-02-17 Mahmut Bilgic Solubility and stability enchancing pharmaceutical formulation
HUE038048T2 (en) * 2009-07-28 2018-09-28 Egyt Gyogyszervegyeszeti Gyar New granulating process and thus prepared granulate
EP2468258A1 (en) * 2010-12-22 2012-06-27 LEK Pharmaceuticals d.d. Process for the preparation of a pharmaceutical composition comprising a low soluble pharmaceutically active ingredient
MX365046B (en) * 2012-05-01 2019-05-17 Althera Life Sciencies Llc Oral tablet formulation consisting of fixed combination of rosuvastatin and ezetimibe for treatment of hyperlipidemia and cardiovascular diseases.

Also Published As

Publication number Publication date
TW201625223A (en) 2016-07-16
KR20160000762A (en) 2016-01-05
ECSP16096477A (en) 2017-01-31
CL2016003283A1 (en) 2017-07-28
BR112016030111A2 (en) 2017-08-22
WO2015199356A1 (en) 2015-12-30
TWI700100B (en) 2020-08-01
JOP20150154B1 (en) 2021-08-17
KR101977785B1 (en) 2019-05-14
UY36190A (en) 2015-10-30
SG11201610748RA (en) 2017-01-27
AR100977A1 (en) 2016-11-16

Similar Documents

Publication Publication Date Title
SG10201811586YA (en) Composite formulation for oral administration comprising ezetimibe and rosuvastatin and a process for the preparation thereof
PH12016501196A1 (en) Composite formulation for oral administration comprising ezetimibe and rosuvastatin
SG10201902598VA (en) Peptidomimetic macrocycles and formulations thereof
EP3133068A4 (en) Amide derivatives and pharmaceutically acceptable salts thereof, preparation method therefor and medicinal application thereof
SG10201804817TA (en) Delayed release compositions of linaclotide
EP3173412A4 (en) 2,4-disubstituted 7h-pyrrolo[2,3-d]pyrimidine derivative, preparation method and medicinal use thereof
EP3096763A4 (en) Novel process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof
PH12017502376A1 (en) Oral solid formulation containing irinotecan and method of preparing the same
EP3590498A4 (en) Preparation, comprising inclusion complex of varenicline or pharmaceutically acceptable salt thereof, for oral administration
EP3498264A4 (en) Pharmaceutical preparation for oral administration with controlled dissolution rate, the preparation comprising tamsulosin hydrochloride-containing sustained-release pellets
IN2015DN03921A (en)
PH12016502243A1 (en) Pharmaceutical compositions for treating infectious diseases
MX2015013155A (en) Tetrandrine family pharmaceutical formulations and method.
EP3158998A4 (en) Pharmaceutical preparation containing entecavir as active ingredient, and preparation method therefor
SG11201912827TA (en) 7-substituted pyrrolotriazine compounds or pharmaceutically acceptable salts thereof, and preparation methods and uses thereof
HK1214600A1 (en) Phosphorus-containing pyrido[2,3-d]pyrimidin-7-ones or their pharmaceutically acceptable salts, pharmaceutical compositions containing this compound and use thereof [23-d]-7-
EP3530654A4 (en) Quinolinyl-substituted carboxylic acid compound or pharmaceutically acceptable salt thereof, pharmaceutical composition thereof, and use thereof
TR201722603A2 (en) Tablet formulations comprising metformin and sitagliptin processed with hot-melt extrusion
WO2018119108A8 (en) Solid pharmaceutical formulations of asimadoline
PH12016502540A1 (en) Pharmaceutical dosage forms
WO2016126115A3 (en) Pharmaceutical composition comprising pitavastatin or a pharmaceutically acceptable salt thereof, and valsartan or a pharmaceutically acceptable salt thereof
TW201613600A (en) Piperazinyl derivative reduces HFD-induced accumulation of fat in the liver, therapeutically
AU2017900496A0 (en) Compounds for Enhancing the Permeation of Active Pharmaceutical Ingredients through Skin
WO2018084817A3 (en) A new form of active agent
NZ728386A (en) Use of phthalide compound